ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
$5.17 -0.71 (-12.08%)
As of 05/18/2022 16:00:02 EST IEX book CBOE book
Security Information
Category1:
US EquityCategory2:
Common stocksCategory3:
Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Canada
Country of incorporation: Canada
IPO date: 04/28/2017
Outstanding shares: 57,771,204
Average volume: 3,499,964
Market cap: $308,498,229
Current dividend yield: 0.00%
All SEC filings:
SEC Edgar Online
Quarterly filings:
10-Q
Annual filings:
10-K
Sedol:
Valuation (See tab for details)
PE ratio: -1.42
PB ratio: 1.10
PS ratio: 8.80
Return on equity: -100.36%
Net income %: -808.72%